Background: Pancreatic adenocarcinoma (PAAD) is an aggressive subtype of pancreatic cancer that is estimated to have a 5-year overall survival rate of only 13%. Most patients present with advanced disease with unpredictable outcomes. The identification of prognostic biomarkers is important to accurately stratify these patients. Methods: We investigated the molecular and survival-related role ofENHOin PAAD by analyzing TGCA mRNA and miRNA data. Survival analysis was conducted using TIMER2.0, “survival”, and “survminer”. Gene set enrichment analysis was conducted using enrichr, while miRNA-mRNA interactions were identified using “multiMiR”. Immune infiltration was assessed using CIBERSORT ABS and ImmuCellAI. Results: We observed thatENHOwas strikingly downregulated in PAAD tissues (p= 3.68 × 10−68), and patients with higherENHOlevels enjoyed significantly better overall survival (HR = 0.597; 95% CI: 0.419–0.852;p< 0.01). Pathway analysis showed that genes co-upregulated withENHOwere enriched for insulin secretion and ion channel activity, whereas those co-downregulated were related to epithelial–mesenchymal transition and extracellular matrix remodeling. HigherENHOalso tracked with increased CD8+T-cell infiltration and correlated positively with PDCD1 and LAG3 but negatively with B7-H3, CD70, and NT5E. Conclusions: Our results point to a protective role forENHOin pancreatic adenocarcinoma.
背景：胰腺导管腺癌（PAAD）是胰腺癌的一种侵袭性亚型，其五年总生存率估计仅为13%。多数患者就诊时已处于晚期，预后难以预测。因此，识别预后生物标志物对于准确分层这些患者至关重要。方法：我们通过分析TGCA的mRNA和miRNA数据，研究了ENHO在PAAD中的分子及生存相关作用。生存分析使用TIMER2.0、“survival”和“survminer”进行。基因集富集分析采用enrichr完成，而miRNA-mRNA相互作用则通过“multiMiR”识别。免疫浸润评估使用了CIBERSORT ABS和ImmuCellAI。结果：我们观察到ENHO在PAAD组织中显著下调（p = 3.68 × 10⁻⁶⁸），且ENHO水平较高的患者总生存期显著更优（HR = 0.597；95% CI：0.419–0.852；p < 0.01）。通路分析显示，与ENHO共同上调的基因富集于胰岛素分泌和离子通道活性，而共同下调的基因则与上皮-间质转化及细胞外基质重塑相关。较高的ENHO水平还与CD8⁺ T细胞浸润增加相关，并与PDCD1和LAG3呈正相关，而与B7-H3、CD70和NT5E呈负相关。结论：我们的研究结果表明ENHO在胰腺导管腺癌中具有保护作用。
The Role of ENHO in Pancreatic Adenocarcinoma: A Bioinformatics Approach
肿瘤(癌症)患者之家